Biogen Inc. (BIIB)
NASDAQ: BIIB
· Real-Time Price · USD
140.67
0.73 (0.52%)
At close: Sep 05, 2025, 3:59 PM
140.34
-0.23%
After-hours: Sep 05, 2025, 05:30 PM EDT
Biogen Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fumarate Revenue | 405.9M | 344.9M | 404.4M | 390.9M | 418M | 381.8M | 400.7M | 405M | 400.4M | 382.7M | 447.9M | 476.8M | 534.7M | 537.9M | 611.4M | 619.5M | 578.5M | 552.9M | 967.5M | 1.19B | 466M | 530M | 554.4M | 500.9M | 590.1M | 625.5M | 550.3M |
| Fumarate Revenue Growth | +17.69% | -14.71% | +3.45% | -6.48% | +9.48% | -4.72% | -1.06% | +1.15% | +4.63% | -14.56% | -6.06% | -10.83% | -0.59% | -12.02% | -1.31% | +7.09% | +4.63% | -42.85% | -18.72% | +155.43% | -12.08% | -4.40% | +10.68% | -15.12% | -5.66% | +13.67% | n/a |
| Interferon Revenue | 246.7M | 226.3M | 236M | 237.5M | 250.9M | 243.6M | 280M | 277.7M | 302.4M | 245.6M | 309.6M | 336M | 350.2M | 309.6M | 377.7M | 387.5M | 400.4M | 400.5M | 474.1M | 481.4M | 2.12B | 2.16B | 2.2B | 1.98B | 467.7M | 422.7M | 363.9M |
| Interferon Revenue Growth | +9.01% | -4.11% | -0.63% | -5.34% | +3.00% | -13.00% | +0.83% | -8.17% | +23.13% | -20.67% | -7.86% | -4.05% | +13.11% | -18.03% | -2.53% | -3.22% | -0.02% | -15.52% | -1.52% | -77.27% | -1.98% | -1.99% | +11.14% | +323.99% | +10.65% | +16.16% | n/a |
| MS Product Revenues Revenue | 1.11B | 953M | 1.07B | 1.05B | 1.15B | 1.08B | 1.17B | 1.16B | 1.21B | 1.13B | 1.27B | 1.34B | 1.43B | 1.39B | 1.53B | 1.56B | 1.53B | 1.48B | 1.98B | 2.13B | 565M | 547.1M | 488.2M | 518.5M | 470.2M | 467.2M | 462.1M |
| MS Product Revenues Revenue Growth | +16.18% | -10.95% | +1.55% | -8.34% | +6.87% | -7.92% | +0.81% | -4.16% | +7.47% | -11.32% | -5.33% | -6.05% | +2.30% | -8.75% | -1.79% | +1.75% | +3.09% | -25.27% | -6.67% | +276.41% | +3.27% | +12.06% | -5.84% | +10.27% | +0.64% | +1.10% | n/a |
| SPINRAZA Revenue | 392.7M | 423.9M | 421.4M | 381.4M | 429.1M | 341.3M | 412.6M | 448.2M | 437.1M | 443.3M | 458.8M | 431.1M | 431.1M | 472.5M | 440.8M | 444.1M | 499.7M | 520.5M | 494.4M | 494.6M | 522.4M | 483.6M | 475.3M | 460.4M | n/a | n/a | n/a |
| SPINRAZA Revenue Growth | -7.36% | +0.59% | +10.49% | -11.12% | +25.73% | -17.28% | -7.94% | +2.54% | -1.40% | -3.38% | +6.43% | 0.00% | -8.76% | +7.19% | -0.74% | -11.13% | -4.00% | +5.28% | -0.04% | -5.32% | +8.02% | +1.75% | +3.24% | n/a | n/a | n/a | n/a |
| TYSABRI product Revenue | 454.6M | 381.5M | 415.4M | 406.1M | 462.2M | 431.3M | 464.7M | 456.3M | 483.1M | 472.8M | 488.4M | 505.5M | 516.2M | 520.8M | 512.8M | 522.8M | 524.2M | 503.3M | 516.5M | 432M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TYSABRI product Revenue Growth | +19.16% | -8.16% | +2.29% | -12.14% | +7.16% | -7.19% | +1.84% | -5.55% | +2.18% | -3.19% | -3.38% | -2.07% | -0.88% | +1.56% | -1.91% | -0.27% | +4.15% | -2.56% | +19.56% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 937.6M | 972.7M | 1B | 956.4M | 1.05B | 965.8M | 848.1M | 1.01B | 1.04B | 1.06B | 849.6M | 1.11B | 1.16B | 1.19B | 955.2M | 1.23B | 1.26B | 1.31B | 1.2B | 1.19B | 1.07B | 1.32B | 1.17B | 1.19B | 1.14B | 1.17B | n/a | 1.04B | 1.02B | 985.5M |
| Non-Us Revenue Growth | -3.61% | -2.84% | +4.67% | -9.17% | +9.02% | +13.88% | -16.39% | -2.92% | -1.61% | +24.99% | -23.58% | -4.23% | -2.54% | +24.70% | -22.48% | -2.11% | -4.05% | +8.91% | +1.05% | +11.00% | -18.72% | +12.87% | -1.84% | +5.00% | -2.64% | n/a | -100.00% | +2.36% | +3.05% | n/a |
| United States Revenue | 941.1M | 753.8M | 831.5M | 813M | 846.7M | 746.1M | n/a | 790.9M | 801M | 701.4M | 1.05B | 850.4M | 894.1M | 875.2M | 1.24B | 973.5M | 977.2M | 899.8M | 1.1B | 1.5B | 1.72B | 1.58B | 1.75B | 1.7B | 1.74B | 1.51B | n/a | 1.74B | 1.74B | 1.54B |
| United States Revenue Growth | +24.85% | -9.34% | +2.28% | -3.98% | +13.48% | n/a | n/a | -1.26% | +14.20% | -33.51% | +24.05% | -4.89% | +2.16% | -29.32% | +27.20% | -0.38% | +8.60% | -17.98% | -26.78% | -12.98% | +8.75% | -9.74% | +3.06% | -2.43% | +15.27% | n/a | n/a | -0.08% | +13.26% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 583.8M | 572.5M | 680M | 588.4M | 553.8M | 581.5M | 608.5M | 788.2M | 548M | 605M | 632.8M | 563.3M | 572.6M | 634.9M | 787.9M | 654.1M | 637.3M | 595M | 806.3M | 573.1M | 555.1M | 570.1M | 664.9M | 554.5M | 587.6M | 567.7M | 591.1M | 497.7M | 516.2M | 501.3M | 572.4M | 433.8M | 430.2M | 499.1M | 495.5M | 462.7M | 492.4M | 497.3M | 583M | 477.83M | 491.89M | 560.36M |
| Selling, General, and Administrative Revenue Growth | +1.97% | -15.81% | +15.57% | +6.25% | -4.76% | -4.44% | -22.80% | +43.83% | -9.42% | -4.39% | +12.34% | -1.62% | -9.81% | -19.42% | +20.46% | +2.64% | +7.11% | -26.21% | +40.69% | +3.24% | -2.63% | -14.26% | +19.91% | -5.63% | +3.51% | -3.96% | +18.77% | -3.58% | +2.97% | -12.42% | +31.95% | +0.84% | -13.80% | +0.73% | +7.09% | -6.03% | -0.99% | -14.70% | +22.01% | -2.86% | -12.22% | n/a |
| Research and Development Revenue | 399M | 434.1M | 532.3M | 542.7M | 513.9M | 445.4M | 647.5M | 736.3M | 584.2M | 570.6M | 601.6M | 549.2M | 528.6M | 551.7M | 699.5M | 702.4M | 585.1M | 514.2M | 1.73B | 1.14B | 647.6M | 476.3M | 691.7M | 540.4M | 484.8M | 563.7M | 611.6M | 507.9M | 981M | 496.7M | 587.6M | 446.4M | 796.2M | 423.4M | 533.9M | 529M | 473.1M | 437.3M | 541.7M | 519.86M | 490.73M | 460.55M |
| Research and Development Revenue Growth | -8.09% | -18.45% | -1.92% | +5.60% | +15.38% | -31.21% | -12.06% | +26.04% | +2.38% | -5.15% | +9.54% | +3.90% | -4.19% | -21.13% | -0.41% | +20.05% | +13.79% | -70.21% | +51.28% | +76.17% | +35.96% | -31.14% | +28.00% | +11.47% | -14.00% | -7.83% | +20.42% | -48.23% | +97.50% | -15.47% | +31.63% | -43.93% | +88.05% | -20.70% | +0.93% | +11.82% | +8.19% | -19.27% | +4.20% | +5.94% | +6.55% | n/a |